speb/financial-data huggingface dataset:
BIOCON.NS balance_sheet (quarterly, 2026-03-31) — Current Provisions: 2555000000.00
BIOCON.NS cash_flow (annual, 2026-03-31) — Deferred Tax: 791000000.00
BIOCON.NS cash_flow (annual, 2026-03-31) — Depreciation: 11545000000.00
BIOCON.NS cash_flow (annual, 2026-03-31) — Depreciation And Amortization: 19567000000.00
BIOCON.NS income_statement (annual, 2026-03-31) — Depreciation And Amortization In Income Statement: 19567000000.00
BIOCON.NS income_statement (quarterly, 2026-03-31) — Depreciation And Amortization In Income Statement: 5134000000.00
BIOCON.NS income_statement (annual, 2026-03-31) — Depreciation Income Statement: 11545000000.00
BIOCON.NS income_statement (quarterly, 2026-03-31) — Depreciation Income Statement: 5134000000.00
BIOCON.NS balance_sheet (annual, 2026-03-31) — Derivative Product Liabilities: 683000000.00
BIOCON.NS balance_sheet (quarterly, 2026-03-31) — Derivative Product Liabilities: 683000000.00
BIOCON.NS income_statement (annual, 2026-03-31) — Diluted Average Shares: 1368563074.00
BIOCON.NS income_statement (quarterly, 2026-03-31) — Diluted Average Shares: 1593670886.00
BIOCON.NS income_statement (annual, 2026-03-31) — Diluted EPS: 2.82
BIOCON.NS income_statement (quarterly, 2026-03-31) — Diluted EPS: 0.79
BIOCON.NS income_statement (annual, 2026-03-31) — Diluted NI Availto Com Stockholders: 3856000000.00
BIOCON.NS income_statement (quarterly, 2026-03-31) — Diluted NI Availto Com Stockholders: 1259000000.00
BIOCON.NS balance_sheet (annual, 2026-03-31) — Dividends Payable: 5000000.00
BIOCON.NS balance_sheet (quarterly, 2026-03-31) — Dividends Payable: 5000000.00
BIOCON.NS cash_flow (annual, 2026-03-31) — Dividends Received Cfi: 0.00
BIOCON.NS income_statement (annual, 2026-03-31) — EBIT: 14127000000.00
BIOCON.NS income_statement (quarterly, 2026-03-31) — EBIT: 4790000000.00
BIOCON.NS income_statement (annual, 2026-03-31) — EBITDA: 33694000000.00
BIOCON.NS income_statement (quarterly, 2026-03-31) — EBITDA: 9924000000.00
BIOCON.NS cash_flow (annual, 2026-03-31) — Effect Of Exchange Rate Changes: 1994000000.00
BIOCON.NS cash_flow (annual, 2026-03-31) — End Cash Position: 21115000000.00
BIOCON.NS balance_sheet (annual, 2026-03-31) — Financial Assets: 430000000.00
BIOCON.NS balance_sheet (quarterly, 2026-03-31) — Financial Assets: 430000000.00
BIOCON.NS balance_sheet (annual, 2026-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 622000000.00
BIOCON.NS balance_sheet (quarterly, 2026-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 622000000.00
BIOCON.NS cash_flow (annual, 2026-03-31) — Financing Cash Flow: -9236000000.00
BIOCON.NS balance_sheet (annual, 2026-03-31) — Finished Goods: 21069000000.00
BIOCON.NS balance_sheet (quarterly, 2026-03-31) — Finished Goods: 21069000000.00
BIOCON.NS balance_sheet (annual, 2026-03-31) — Fixed Assets Revaluation Reserve: 9000000.00
BIOCON.NS balance_sheet (quarterly, 2026-03-31) — Fixed Assets Revaluation Reserve: 9000000.00
BIOCON.NS cash_flow (annual, 2026-03-31) — Free Cash Flow: 823000000.00
BIOCON.NS cash_flow (annual, 2026-03-31) — Gain Loss On Investment Securities: -1632000000.00
BIOCON.NS cash_flow (annual, 2026-03-31) — Gain Loss On Sale Of PPE: 158000000.00
BIOCON.NS income_statement (annual, 2026-03-31) — General And Administrative Expense: 6744000000.00
BIOCON.NS balance_sheet (annual, 2026-03-31) — Goodwill: 183775000000.00
BIOCON.NS balance_sheet (quarterly, 2026-03-31) — Goodwill: 183775000000.00
BIOCON.NS balance_sheet (annual, 2026-03-31) — Goodwill And Other Intangible Assets: 288091000000.00
BIOCON.NS balance_sheet (quarterly, 2026-03-31) — Goodwill And Other Intangible Assets: 288091000000.00
BIOCON.NS balance_sheet (annual, 2026-03-31) — Gross Accounts Receivable: 60718000000.00
BIOCON.NS balance_sheet (quarterly, 2026-03-31) — Gross Accounts Receivable: 60718000000.00
BIOCON.NS balance_sheet (annual, 2026-03-31) — Gross PPE: 227240000000.00
BIOCON.NS balance_sheet (quarterly, 2026-03-31) — Gross PPE: 227240000000.00
BIOCON.NS income_statement (annual, 2026-03-31) — Gross Profit: 110851000000.00
BIOCON.NS income_statement (quarterly, 2026-03-31) — Gross Profit: 30850000000.00
BIOCON.NS balance_sheet (annual, 2026-03-31) — Hedging Assets Current: 218000000.00
BIOCON.NS balance_sheet (quarterly, 2026-03-31) — Hedging Assets Current: 218000000.00
BIOCON.NS income_statement (annual, 2026-03-31) — Interest Expense: 9648000000.00
BIOCON.NS income_statement (quarterly, 2026-03-31) — Interest Expense: 2315000000.00
BIOCON.NS income_statement (annual, 2026-03-31) — Interest Expense Non Operating: 9648000000.00
BIOCON.NS income_statement (quarterly, 2026-03-31) — Interest Expense Non Operating: 2315000000.00
BIOCON.NS income_statement (annual, 2026-03-31) — Interest Income: 1154000000.00
BIOCON.NS income_statement (annual, 2026-03-31) — Interest Income Non Operating: 1154000000.00
BIOCON.NS cash_flow (annual, 2026-03-31) — Interest Paid Cff: -8654000000.00
BIOCON.NS cash_flow (annual, 2026-03-31) — Interest Received Cfi: 1480000000.00
BIOCON.NS balance_sheet (annual, 2026-03-31) — Inventory: 60857000000.00
BIOCON.NS balance_sheet (quarterly, 2026-03-31) — Inventory: 60857000000.00
BIOCON.NS balance_sheet (annual, 2026-03-31) — Invested Capital: 488565000000.00
BIOCON.NS balance_sheet (quarterly, 2026-03-31) — Invested Capital: 488565000000.00
BIOCON.NS cash_flow (annual, 2026-03-31) — Investing Cash Flow: -20821000000.00
BIOCON.NS balance_sheet (annual, 2026-03-31) — Investmentin Financial Assets: 14399000000.00
BIOCON.NS balance_sheet (quarterly, 2026-03-31) — Investmentin Financial Assets: 14399000000.00
BIOCON.NS cash_flow (annual, 2026-03-31) — Issuance Of Capital Stock: 86015000000.00
BIOCON.NS cash_flow (annual, 2026-03-31) — Issuance Of Debt: 3013000000.00
BIOCON.NS balance_sheet (annual, 2026-03-31) — Land And Improvements: 4277000000.00
BIOCON.NS balance_sheet (quarterly, 2026-03-31) — Land And Improvements: 4277000000.00
BIOCON.NS balance_sheet (annual, 2026-03-31) — Long Term Capital Lease Obligation: 5370000000.00
BIOCON.NS balance_sheet (quarterly, 2026-03-31) — Long Term Capital Lease Obligation: 5370000000.00
BIOCON.NS balance_sheet (annual, 2026-03-31) — Long Term Debt: 107463000000.00
BIOCON.NS balance_sheet (quarterly, 2026-03-31) — Long Term Debt: 107463000000.00
BIOCON.NS balance_sheet (annual, 2026-03-31) — Long Term Debt And Capital Lease Obligation: 112833000000.00
BIOCON.NS balance_sheet (quarterly, 2026-03-31) — Long Term Debt And Capital Lease Obligation: 112833000000.00
BIOCON.NS cash_flow (annual, 2026-03-31) — Long Term Debt Issuance: 2664000000.00
BIOCON.NS cash_flow (annual, 2026-03-31) — Long Term Debt Payments: -27079000000.00
BIOCON.NS balance_sheet (annual, 2026-03-31) — Long Term Provisions: 3303000000.00
BIOCON.NS balance_sheet (quarterly, 2026-03-31) — Long Term Provisions: 3303000000.00
BIOCON.NS balance_sheet (annual, 2026-03-31) — Machinery Furniture Equipment: 131454000000.00
BIOCON.NS balance_sheet (quarterly, 2026-03-31) — Machinery Furniture Equipment: 131454000000.00
BIOCON.NS balance_sheet (annual, 2026-03-31) — Minority Interest: 25897000000.00
BIOCON.NS balance_sheet (quarterly, 2026-03-31) — Minority Interest: 25897000000.00
BIOCON.NS income_statement (annual, 2026-03-31) — Minority Interests: 168000000.00
BIOCON.NS income_statement (quarterly, 2026-03-31) — Minority Interests: -727000000.00
BIOCON.NS cash_flow (annual, 2026-03-31) — Net Business Purchase And Sale: 0.00
BIOCON.NS cash_flow (annual, 2026-03-31) — Net Common Stock Issuance: 85989000000.00
BIOCON.NS balance_sheet (annual, 2026-03-31) — Net Debt: 124087000000.00
BIOCON.NS balance_sheet (quarterly, 2026-03-31) — Net Debt: 124087000000.00
BIOCON.NS cash_flow (annual, 2026-03-31) — Net Foreign Currency Exchange Gain Loss: -397000000.00
BIOCON.NS income_statement (annual, 2026-03-31) — Net Income: 3856000000.00
BIOCON.NS income_statement (quarterly, 2026-03-31) — Net Income: 1259000000.00
BIOCON.NS income_statement (annual, 2026-03-31) — Net Income Common Stockholders: 3856000000.00
BIOCON.NS income_statement (quarterly, 2026-03-31) — Net Income Common Stockholders: 1259000000.00
BIOCON.NS income_statement (annual, 2026-03-31) — Net Income Continuous Operations: 3688000000.00
BIOCON.NS income_statement (quarterly, 2026-03-31) — Net Income Continuous Operations: 1986000000.00
BIOCON.NS income_statement (annual, 2026-03-31) — Net Income From Continuing And Discontinued Operation: 3856000000.00
BIOCON.NS income_statement (quarterly, 2026-03-31) — Net Income From Continuing And Discontinued Operation: 1259000000.00
BIOCON.NS income_statement (annual, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: 3856000000.00
BIOCON.NS income_statement (quarterly, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: 1259000000.00
BIOCON.NS cash_flow (annual, 2026-03-31) — Net Income From Continuing Operations: 3688000000.00
BIOCON.NS income_statement (annual, 2026-03-31) — Net Income Including Noncontrolling Interests: 3688000000.00
BIOCON.NS income_statement (quarterly, 2026-03-31) — Net Income Including Noncontrolling Interests: 1986000000.00
BIOCON.NS cash_flow (annual, 2026-03-31) — Net Intangibles Purchase And Sale: -1138000000.00
BIOCON.NS income_statement (annual, 2026-03-31) — Net Interest Income: -8749000000.00
BIOCON.NS income_statement (quarterly, 2026-03-31) — Net Interest Income: -2315000000.00
BIOCON.NS cash_flow (annual, 2026-03-31) — Net Investment Purchase And Sale: -3184000000.00
BIOCON.NS cash_flow (annual, 2026-03-31) — Net Issuance Payments Of Debt: -24066000000.00
BIOCON.NS cash_flow (annual, 2026-03-31) — Net Long Term Debt Issuance: -24415000000.00
BIOCON.NS income_statement (annual, 2026-03-31) — Net Non Operating Interest Income Expense: -8749000000.00
BIOCON.NS income_statement (quarterly, 2026-03-31) — Net Non Operating Interest Income Expense: -2315000000.00
BIOCON.NS cash_flow (annual, 2026-03-31) — Net Other Financing Charges: -59652000000.00
BIOCON.NS balance_sheet (annual, 2026-03-31) — Net PPE: 147341000000.00
BIOCON.NS balance_sheet (quarterly, 2026-03-31) — Net PPE: 147341000000.00
BIOCON.NS cash_flow (annual, 2026-03-31) — Net PPE Purchase And Sale: -17979000000.00
BIOCON.NS cash_flow (annual, 2026-03-31) — Net Short Term Debt Issuance: 349000000.00
BIOCON.NS balance_sheet (annual, 2026-03-31) — Net Tangible Assets: 52227000000.00
BIOCON.NS balance_sheet (quarterly, 2026-03-31) — Net Tangible Assets: 52227000000.00
BIOCON.NS balance_sheet (annual, 2026-03-31) — Non Current Deferred Revenue: 4813000000.00
BIOCON.NS balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Revenue: 4813000000.00
BIOCON.NS balance_sheet (annual, 2026-03-31) — Non Current Deferred Taxes Assets: 5556000000.00
BIOCON.NS balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Taxes Assets: 5556000000.00
BIOCON.NS balance_sheet (annual, 2026-03-31) — Non Current Deferred Taxes Liabilities: 2417000000.00
BIOCON.NS balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Taxes Liabilities: 2417000000.00
BIOCON.NS balance_sheet (annual, 2026-03-31) — Non Current Prepaid Assets: 1990000000.00
BIOCON.NS balance_sheet (quarterly, 2026-03-31) — Non Current Prepaid Assets: 1990000000.00
BIOCON.NS income_statement (annual, 2026-03-31) — Normalized EBITDA: 36527000000.00
BIOCON.NS income_statement (quarterly, 2026-03-31) — Normalized EBITDA: 10728000000.00
BIOCON.NS income_statement (annual, 2026-03-31) — Normalized Income: 6094070000.00
BIOCON.NS income_statement (quarterly, 2026-03-31) — Normalized Income: 1904149090.91
BIOCON.NS cash_flow (annual, 2026-03-31) — Operating Cash Flow: 19940000000.00
BIOCON.NS income_statement (annual, 2026-03-31) — Operating Income: 17221000000.00
BIOCON.NS income_statement (quarterly, 2026-03-31) — Operating Income: 5069000000.00
BIOCON.NS income_statement (annual, 2026-03-31) — Operating Revenue: 167799000000.00
BIOCON.NS income_statement (quarterly, 2026-03-31) — Operating Revenue: 44843000000.00
BIOCON.NS balance_sheet (annual, 2026-03-31) — Ordinary Shares Number: 1619507375.00
BIOCON.NS balance_sheet (quarterly, 2026-03-31) — Ordinary Shares Number: 1619507375.00
BIOCON.NS balance_sheet (annual, 2026-03-31) — Other Current Assets: 8871000000.00
BIOCON.NS balance_sheet (quarterly, 2026-03-31) — Other Current Assets: 8871000000.00
BIOCON.NS balance_sheet (annual, 2026-03-31) — Other Current Liabilities: 388000000.00
BIOCON.NS balance_sheet (quarterly, 2026-03-31) — Other Current Liabilities: 388000000.00
BIOCON.NS balance_sheet (annual, 2026-03-31) — Other Equity Interest: 4488000000.00
BIOCON.NS balance_sheet (quarterly, 2026-03-31) — Other Equity Interest: 4488000000.00
BIOCON.NS balance_sheet (annual, 2026-03-31) — Other Intangible Assets: 104316000000.00
BIOCON.NS balance_sheet (quarterly, 2026-03-31) — Other Intangible Assets: 104316000000.00
BIOCON.NS balance_sheet (annual, 2026-03-31) — Other Inventories: 4414000000.00
BIOCON.NS balance_sheet (quarterly, 2026-03-31) — Other Inventories: 4414000000.00
BIOCON.NS cash_flow (annual, 2026-03-31) — Other Non Cash Items: 9345000000.00
BIOCON.NS balance_sheet (annual, 2026-03-31) — Other Non Current Assets: 2848000000.00
BIOCON.NS balance_sheet (quarterly, 2026-03-31) — Other Non Current Assets: 2848000000.00
BIOCON.NS balance_sheet (annual, 2026-03-31) — Other Non Current Liabilities: 5550000000.00
BIOCON.NS balance_sheet (quarterly, 2026-03-31) — Other Non Current Liabilities: 5550000000.00
BIOCON.NS income_statement (annual, 2026-03-31) — Other Non Operating Income Expenses: 639000000.00
BIOCON.NS income_statement (quarterly, 2026-03-31) — Other Non Operating Income Expenses: 525000000.00
BIOCON.NS income_statement (annual, 2026-03-31) — Other Operating Expenses: 19178000000.00
BIOCON.NS income_statement (quarterly, 2026-03-31) — Other Operating Expenses: 11977000000.00
BIOCON.NS balance_sheet (annual, 2026-03-31) — Other Payable: 9662000000.00
BIOCON.NS balance_sheet (quarterly, 2026-03-31) — Other Payable: 9662000000.00
BIOCON.NS balance_sheet (annual, 2026-03-31) — Other Properties: 4507000000.00
BIOCON.NS balance_sheet (quarterly, 2026-03-31) — Other Properties: 4507000000.00
BIOCON.NS balance_sheet (annual, 2026-03-31) — Other Receivables: 1550000000.00
BIOCON.NS balance_sheet (quarterly, 2026-03-31) — Other Receivables: 1550000000.00
BIOCON.NS balance_sheet (annual, 2026-03-31) — Other Short Term Investments: 16266000000.00
BIOCON.NS balance_sheet (quarterly, 2026-03-31) — Other Short Term Investments: 16266000000.00
BIOCON.NS income_statement (annual, 2026-03-31) — Other Special Charges: 4187000000.00
BIOCON.NS income_statement (annual, 2026-03-31) — Otherunder Preferred Stock Dividend: 0.00
BIOCON.NS income_statement (quarterly, 2026-03-31) — Otherunder Preferred Stock Dividend: 0.00
BIOCON.NS balance_sheet (annual, 2026-03-31) — Payables: 85790000000.00
BIOCON.NS balance_sheet (quarterly, 2026-03-31) — Payables: 85790000000.00
BIOCON.NS balance_sheet (annual, 2026-03-31) — Prepaid Assets: 8871000000.00
BIOCON.NS balance_sheet (quarterly, 2026-03-31) — Prepaid Assets: 8871000000.00
BIOCON.NS income_statement (annual, 2026-03-31) — Pretax Income: 4479000000.00
BIOCON.NS income_statement (quarterly, 2026-03-31) — Pretax Income: 2475000000.00
BIOCON.NS balance_sheet (annual, 2026-03-31) — Properties: 0.00
BIOCON.NS balance_sheet (quarterly, 2026-03-31) — Properties: 0.00
BIOCON.NS cash_flow (annual, 2026-03-31) — Provisionand Write Offof Assets: 251000000.00
BIOCON.NS cash_flow (annual, 2026-03-31) — Purchase Of Intangibles: -1138000000.00
BIOCON.NS cash_flow (annual, 2026-03-31) — Purchase Of Investment: -235358000000.00
BIOCON.NS cash_flow (annual, 2026-03-31) — Purchase Of PPE: -17979000000.00
BIOCON.NS balance_sheet (annual, 2026-03-31) — Raw Materials: 11615000000.00
BIOCON.NS balance_sheet (quarterly, 2026-03-31) — Raw Materials: 11615000000.00
BIOCON.NS income_statement (annual, 2026-03-31) — Reconciled Cost Of Revenue: 56948000000.00
BIOCON.NS income_statement (quarterly, 2026-03-31) — Reconciled Cost Of Revenue: 13993000000.00
BIOCON.NS income_statement (annual, 2026-03-31) — Reconciled Depreciation: 19567000000.00
BIOCON.NS income_statement (quarterly, 2026-03-31) — Reconciled Depreciation: 5134000000.00
BIOCON.NS income_statement (annual, 2026-03-31) — Rent And Landing Fees: 253000000.00
BIOCON.NS income_statement (annual, 2026-03-31) — Rent Expense Supplemental: 253000000.00
BIOCON.NS cash_flow (annual, 2026-03-31) — Repayment Of Debt: -27079000000.00
BIOCON.NS cash_flow (annual, 2026-03-31) — Repurchase Of Capital Stock: -26000000.00
BIOCON.NS income_statement (annual, 2026-03-31) — Research And Development: 7085000000.00
BIOCON.NS income_statement (quarterly, 2026-03-31) — Research And Development: -128000000.00
BIOCON.NS balance_sheet (annual, 2026-03-31) — Restricted Cash: 8000000.00
BIOCON.NS balance_sheet (quarterly, 2026-03-31) — Restricted Cash: 8000000.00
BIOCON.NS balance_sheet (annual, 2026-03-31) — Retained Earnings: 139920000000.00
BIOCON.NS balance_sheet (quarterly, 2026-03-31) — Retained Earnings: 139920000000.00
BIOCON.NS cash_flow (annual, 2026-03-31) — Sale Of Business: 0.00
BIOCON.NS cash_flow (annual, 2026-03-31) — Sale Of Investment: 232174000000.00
BIOCON.NS cash_flow (annual, 2026-03-31) — Sale Of PPE: 0.00
BIOCON.NS income_statement (annual, 2026-03-31) — Selling And Marketing Expense: 6988000000.00
BIOCON.NS income_statement (annual, 2026-03-31) — Selling General And Administration: 13732000000.00
BIOCON.NS balance_sheet (annual, 2026-03-31) — Share Issued: 1620907773.00
BIOCON.NS balance_sheet (quarterly, 2026-03-31) — Share Issued: 1620907773.00
BIOCON.NS cash_flow (annual, 2026-03-31) — Short Term Debt Issuance: 349000000.00
BIOCON.NS income_statement (annual, 2026-03-31) — Special Income Charges: -4465000000.00
BIOCON.NS income_statement (quarterly, 2026-03-31) — Special Income Charges: -804000000.00
BIOCON.NS cash_flow (annual, 2026-03-31) — Stock Based Compensation: 1639000000.00
BIOCON.NS balance_sheet (annual, 2026-03-31) — Stockholders Equity: 340318000000.00
BIOCON.NS balance_sheet (quarterly, 2026-03-31) — Stockholders Equity: 340318000000.00
BIOCON.NS balance_sheet (annual, 2026-03-31) — Tangible Book Value: 52227000000.00
BIOCON.NS balance_sheet (quarterly, 2026-03-31) — Tangible Book Value: 52227000000.00
BIOCON.NS income_statement (annual, 2026-03-31) — Tax Effect Of Unusual Items: -594930000.00
BIOCON.NS income_statement (quarterly, 2026-03-31) — Tax Effect Of Unusual Items: -158850909.09
BIOCON.NS income_statement (annual, 2026-03-31) — Tax Provision: 791000000.00
BIOCON.NS income_statement (quarterly, 2026-03-31) — Tax Provision: 489000000.00
BIOCON.NS income_statement (annual, 2026-03-31) — Tax Rate For Calcs: 0.21
BIOCON.NS income_statement (quarterly, 2026-03-31) — Tax Rate For Calcs: 0.20
BIOCON.NS cash_flow (annual, 2026-03-31) — Taxes Refund Paid: -2426000000.00
BIOCON.NS balance_sheet (annual, 2026-03-31) — Total Assets: 636506000000.00
BIOCON.NS balance_sheet (quarterly, 2026-03-31) — Total Assets: 636506000000.00
BIOCON.NS balance_sheet (annual, 2026-03-31) — Total Capitalization: 447781000000.00
BIOCON.NS balance_sheet (quarterly, 2026-03-31) — Total Capitalization: 447781000000.00
BIOCON.NS balance_sheet (annual, 2026-03-31) — Total Debt: 154341000000.00
BIOCON.NS balance_sheet (quarterly, 2026-03-31) — Total Debt: 154341000000.00
BIOCON.NS balance_sheet (annual, 2026-03-31) — Total Equity Gross Minority Interest: 366215000000.00
BIOCON.NS balance_sheet (quarterly, 2026-03-31) — Total Equity Gross Minority Interest: 366215000000.00
BIOCON.NS income_statement (annual, 2026-03-31) — Total Expenses: 150578000000.00
BIOCON.NS income_statement (quarterly, 2026-03-31) — Total Expenses: 39774000000.00
BIOCON.NS balance_sheet (annual, 2026-03-31) — Total Liabilities Net Minority Interest: 270291000000.00
BIOCON.NS balance_sheet (quarterly, 2026-03-31) — Total Liabilities Net Minority Interest: 270291000000.00
BIOCON.NS balance_sheet (annual, 2026-03-31) — Total Non Current Assets: 464708000000.00
BIOCON.NS balance_sheet (quarterly, 2026-03-31) — Total Non Current Assets: 464708000000.00
BIOCON.NS balance_sheet (annual, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 129599000000.00
BIOCON.NS balance_sheet (quarterly, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 129599000000.00
BIOCON.NS income_statement (annual, 2026-03-31) — Total Other Finance Cost: 255000000.00
BIOCON.NS balance_sheet (annual, 2026-03-31) — Total Tax Payable: 8402000000.00
BIOCON.NS balance_sheet (quarterly, 2026-03-31) — Total Tax Payable: 8402000000.00
BIOCON.NS income_statement (annual, 2026-03-31) — Total Unusual Items: -2833000000.00
BIOCON.NS income_statement (quarterly, 2026-03-31) — Total Unusual Items: -804000000.00
BIOCON.NS income_statement (annual, 2026-03-31) — Total Unusual Items Excluding Goodwill: -2833000000.00
BIOCON.NS income_statement (quarterly, 2026-03-31) — Total Unusual Items Excluding Goodwill: -804000000.00
BIOCON.NS balance_sheet (annual, 2026-03-31) — Treasury Shares Number: 1400398.00
BIOCON.NS balance_sheet (quarterly, 2026-03-31) — Treasury Shares Number: 1400398.00
BIOCON.NS balance_sheet (annual, 2026-03-31) — Treasury Stock: 423000000.00
BIOCON.NS balance_sheet (quarterly, 2026-03-31) — Treasury Stock: 423000000.00
BIOCON.NS balance_sheet (annual, 2026-03-31) — Work In Process: 23759000000.00
BIOCON.NS balance_sheet (quarterly, 2026-03-31) — Work In Process: 23759000000.00
BIOCON.NS balance_sheet (annual, 2026-03-31) — Working Capital: 31106000000.00
BIOCON.NS balance_sheet (quarterly, 2026-03-31) — Working Capital: 31106000000.00
BIOCON.NS income_statement (annual, 2026-03-31) — Write Off: 278000000.00
BIOFILCHEM.NS income_statement (annual, 2022-03-31) — +Operating Expense: 20169000.00
BIOFILCHEM.NS income_statement (annual, 2022-03-31) — +Total Revenue: 223823000.00
BIOFILCHEM.NS balance_sheet (annual, 2022-03-31) — Accounts Payable: 5963000.00
BIOFILCHEM.NS balance_sheet (annual, 2022-03-31) — Accounts Receivable: 71737000.00
BIOFILCHEM.NS balance_sheet (annual, 2022-03-31) — Accumulated Depreciation: -21977000.00
BIOFILCHEM.NS balance_sheet (annual, 2022-03-31) — Additional Paid In Capital: 83331000.00
BIOFILCHEM.NS balance_sheet (annual, 2022-03-31) — Allowance For Doubtful Accounts Receivable: -339000.00
BIOFILCHEM.NS income_statement (annual, 2022-03-31) — Basic Average Shares: 16273800.00
BIOFILCHEM.NS income_statement (annual, 2022-03-31) — Basic EPS: 0.44
BIOFILCHEM.NS cash_flow (annual, 2022-03-31) — Beginning Cash Position: 4405000.00
BIOFILCHEM.NS balance_sheet (annual, 2022-03-31) — Buildings And Improvements: 29800000.00
BIOFILCHEM.NS cash_flow (annual, 2022-03-31) — Capital Expenditure: -699000.00
BIOFILCHEM.NS balance_sheet (annual, 2022-03-31) — Capital Stock: 162738000.00
BIOFILCHEM.NS balance_sheet (annual, 2022-03-31) — Cash And Cash Equivalents: 1450000.00
BIOFILCHEM.NS balance_sheet (annual, 2022-03-31) — Cash Cash Equivalents And Short Term Investments: 1450000.00
BIOFILCHEM.NS balance_sheet (annual, 2022-03-31) — Cash Equivalents: 0.00
BIOFILCHEM.NS balance_sheet (annual, 2022-03-31) — Cash Financial: 1450000.00
BIOFILCHEM.NS cash_flow (annual, 2022-03-31) — Change In Inventory: 30514000.00
BIOFILCHEM.NS cash_flow (annual, 2022-03-31) — Change In Other Current Assets: 7574000.00
BIOFILCHEM.NS cash_flow (annual, 2022-03-31) — Change In Other Current Liabilities: 61000.00
BIOFILCHEM.NS cash_flow (annual, 2022-03-31) — Change In Payable: -152557000.00
BIOFILCHEM.NS cash_flow (annual, 2022-03-31) — Change In Receivables: 100442000.00
BIOFILCHEM.NS cash_flow (annual, 2022-03-31) — Change In Working Capital: -13966000.00
BIOFILCHEM.NS cash_flow (annual, 2022-03-31) — Changes In Cash: -2956000.00
BIOFILCHEM.NS balance_sheet (annual, 2022-03-31) — Common Stock: 162738000.00
BIOFILCHEM.NS balance_sheet (annual, 2022-03-31) — Common Stock Equity: 168377000.00
BIOFILCHEM.NS balance_sheet (annual, 2022-03-31) — Construction In Progress: 0.00
BIOFILCHEM.NS income_statement (annual, 2022-03-31) — Cost Of Revenue: 194604000.00
BIOFILCHEM.NS balance_sheet (annual, 2022-03-31) — Current Assets: 93130000.00
BIOFILCHEM.NS balance_sheet (annual, 2022-03-31) — Current Debt: 4647000.00
BIOFILCHEM.NS balance_sheet (annual, 2022-03-31) — Current Debt And Capital Lease Obligation: 4647000.00
BIOFILCHEM.NS balance_sheet (annual, 2022-03-31) — Current Deferred Taxes Liabilities: 2710000.00
BIOFILCHEM.NS balance_sheet (annual, 2022-03-31) — Current Liabilities: 14948000.00
BIOFILCHEM.NS balance_sheet (annual, 2022-03-31) — Current Provisions: 2710000.00
BIOFILCHEM.NS cash_flow (annual, 2022-03-31) — Depreciation: 4376000.00
BIOFILCHEM.NS cash_flow (annual, 2022-03-31) — Depreciation And Amortization: 4376000.00
BIOFILCHEM.NS income_statement (annual, 2022-03-31) — Depreciation And Amortization In Income Statement: 4275000.00
BIOFILCHEM.NS income_statement (annual, 2022-03-31) — Depreciation Income Statement: 4275000.00
BIOFILCHEM.NS income_statement (annual, 2022-03-31) — Diluted Average Shares: 16273800.00
BIOFILCHEM.NS income_statement (annual, 2022-03-31) — Diluted EPS: 0.44
BIOFILCHEM.NS income_statement (annual, 2022-03-31) — Diluted NI Availto Com Stockholders: 6984000.00
BIOFILCHEM.NS income_statement (annual, 2022-03-31) — EBIT: 10539000.00
BIOFILCHEM.NS income_statement (annual, 2022-03-31) — EBITDA: 14915000.00
BIOFILCHEM.NS cash_flow (annual, 2022-03-31) — End Cash Position: 1449000.00
BIOFILCHEM.NS cash_flow (annual, 2022-03-31) — Financing Cash Flow: -58000.00
BIOFILCHEM.NS balance_sheet (annual, 2022-03-31) — Finished Goods: 2258000.00
BIOFILCHEM.NS balance_sheet (annual, 2022-03-31) — Fixed Assets Revaluation Reserve: 37621000.00
BIOFILCHEM.NS cash_flow (annual, 2022-03-31) — Free Cash Flow: -2898000.00
BIOFILCHEM.NS income_statement (annual, 2022-03-31) — General And Administrative Expense: 1879000.00
BIOFILCHEM.NS balance_sheet (annual, 2022-03-31) — Gross Accounts Receivable: 72076000.00
BIOFILCHEM.NS balance_sheet (annual, 2022-03-31) — Gross PPE: 116171000.00
BIOFILCHEM.NS income_statement (annual, 2022-03-31) — Gross Profit: 29219000.00
BIOFILCHEM.NS income_statement (annual, 2022-03-31) — Interest Expense: 390000.00
BIOFILCHEM.NS income_statement (annual, 2022-03-31) — Interest Expense Non Operating: 390000.00
BIOFILCHEM.NS income_statement (annual, 2022-03-31) — Interest Income: 210000.00
BIOFILCHEM.NS income_statement (annual, 2022-03-31) — Interest Income Non Operating: 210000.00
BIOFILCHEM.NS cash_flow (annual, 2022-03-31) — Interest Paid Cff: -406000.00
BIOFILCHEM.NS cash_flow (annual, 2022-03-31) — Interest Received Cfi: 0.00
BIOFILCHEM.NS balance_sheet (annual, 2022-03-31) — Inventory: 12932000.00
BIOFILCHEM.NS balance_sheet (annual, 2022-03-31) — Invested Capital: 173024000.00
BIOFILCHEM.NS cash_flow (annual, 2022-03-31) — Investing Cash Flow: -699000.00
BIOFILCHEM.NS balance_sheet (annual, 2022-03-31) — Land And Improvements: 44959000.00
BIOFILCHEM.NS balance_sheet (annual, 2022-03-31) — Machinery Furniture Equipment: 38979000.00
BIOFILCHEM.NS balance_sheet (annual, 2022-03-31) — Net Debt: 3197000.00
BIOFILCHEM.NS income_statement (annual, 2022-03-31) — Net Income: 6984000.00
BIOFILCHEM.NS income_statement (annual, 2022-03-31) — Net Income Common Stockholders: 6984000.00
BIOFILCHEM.NS income_statement (annual, 2022-03-31) — Net Income Continuous Operations: 6984000.00
BIOFILCHEM.NS income_statement (annual, 2022-03-31) — Net Income Discontinuous Operations: 0.00
BIOFILCHEM.NS income_statement (annual, 2022-03-31) — Net Income From Continuing And Discontinued Operation: 6984000.00
BIOFILCHEM.NS income_statement (annual, 2022-03-31) — Net Income From Continuing Operation Net Minority Interest: 6984000.00
BIOFILCHEM.NS cash_flow (annual, 2022-03-31) — Net Income From Continuing Operations: 10149000.00
BIOFILCHEM.NS income_statement (annual, 2022-03-31) — Net Income Including Noncontrolling Interests: 6984000.00
BIOFILCHEM.NS income_statement (annual, 2022-03-31) — Net Interest Income: -196000.00
BIOFILCHEM.NS cash_flow (annual, 2022-03-31) — Net Issuance Payments Of Debt: 348000.00
BIOFILCHEM.NS cash_flow (annual, 2022-03-31) — Net Long Term Debt Issuance: 348000.00
BIOFILCHEM.NS income_statement (annual, 2022-03-31) — Net Non Operating Interest Income Expense: -196000.00
BIOFILCHEM.NS balance_sheet (annual, 2022-03-31) — Net PPE: 94194000.00
BIOFILCHEM.NS cash_flow (annual, 2022-03-31) — Net PPE Purchase And Sale: -699000.00
BIOFILCHEM.NS cash_flow (annual, 2022-03-31) — Net Short Term Debt Issuance: 348000.00
BIOFILCHEM.NS balance_sheet (annual, 2022-03-31) — Net Tangible Assets: 168377000.00
BIOFILCHEM.NS balance_sheet (annual, 2022-03-31) — Non Current Deferred Taxes Liabilities: 3998000.00
BIOFILCHEM.NS income_statement (annual, 2022-03-31) — Normalized EBITDA: 14915000.00
BIOFILCHEM.NS income_statement (annual, 2022-03-31) — Normalized Income: 6984000.00
BIOFILCHEM.NS cash_flow (annual, 2022-03-31) — Operating Cash Flow: -2199000.00
BIOFILCHEM.NS income_statement (annual, 2022-03-31) — Operating Income: 9050000.00
BIOFILCHEM.NS income_statement (annual, 2022-03-31) — Operating Revenue: 223823000.00
BIOFILCHEM.NS balance_sheet (annual, 2022-03-31) — Ordinary Shares Number: 16273800.00
BIOFILCHEM.NS cash_flow (annual, 2022-03-31) — Other Cash Adjustment Outside Changein Cash: -1000.00
BIOFILCHEM.NS balance_sheet (annual, 2022-03-31) — Other Current Assets: 2478000.00
BIOFILCHEM.NS balance_sheet (annual, 2022-03-31) — Other Current Liabilities: -1000.00
BIOFILCHEM.NS balance_sheet (annual, 2022-03-31) — Other Equity Interest: 5639000.00
BIOFILCHEM.NS cash_flow (annual, 2022-03-31) — Other Non Cash Items: 406000.00
BIOFILCHEM.NS balance_sheet (annual, 2022-03-31) — Other Non Current Assets: -1000.00
BIOFILCHEM.NS balance_sheet (annual, 2022-03-31) — Other Non Current Liabilities: -1000.00
BIOFILCHEM.NS income_statement (annual, 2022-03-31) — Other Non Operating Income Expenses: 1293000.00
BIOFILCHEM.NS income_statement (annual, 2022-03-31) — Other Operating Expenses: 5784000.00
BIOFILCHEM.NS balance_sheet (annual, 2022-03-31) — Other Payable: 1628000.00
BIOFILCHEM.NS balance_sheet (annual, 2022-03-31) — Other Properties: 2433000.00
BIOFILCHEM.NS balance_sheet (annual, 2022-03-31) — Other Short Term Investments: 600000.00
BIOFILCHEM.NS income_statement (annual, 2022-03-31) — Otherunder Preferred Stock Dividend: 0.00
BIOFILCHEM.NS balance_sheet (annual, 2022-03-31) — Payables: 7591000.00
BIOFILCHEM.NS cash_flow (annual, 2022-03-31) — Pension And Employee Benefit Expense: 101000.00
BIOFILCHEM.NS balance_sheet (annual, 2022-03-31) — Prepaid Assets: 2480000.00
BIOFILCHEM.NS income_statement (annual, 2022-03-31) — Pretax Income: 10149000.00
BIOFILCHEM.NS balance_sheet (annual, 2022-03-31) — Properties: 0.00
BIOFILCHEM.NS cash_flow (annual, 2022-03-31) — Purchase Of PPE: -699000.00
BIOFILCHEM.NS balance_sheet (annual, 2022-03-31) — Raw Materials: 9639000.00
BIOFILCHEM.NS income_statement (annual, 2022-03-31) — Reconciled Cost Of Revenue: 194604000.00
BIOFILCHEM.NS income_statement (annual, 2022-03-31) — Reconciled Depreciation: 4376000.00
BIOFILCHEM.NS balance_sheet (annual, 2022-03-31) — Restricted Cash: 0.00
BIOFILCHEM.NS balance_sheet (annual, 2022-03-31) — Retained Earnings: -330595000.00
BIOFILCHEM.NS cash_flow (annual, 2022-03-31) — Sale Of PPE: 0.00
BIOFILCHEM.NS income_statement (annual, 2022-03-31) — Selling And Marketing Expense: 74000.00
BIOFILCHEM.NS income_statement (annual, 2022-03-31) — Selling General And Administration: 1953000.00
BIOFILCHEM.NS balance_sheet (annual, 2022-03-31) — Share Issued: 16273800.00
BIOFILCHEM.NS income_statement (annual, 2022-03-31) — Special Income Charges: 0.00
BIOFILCHEM.NS balance_sheet (annual, 2022-03-31) — Stockholders Equity: 168377000.00
BIOFILCHEM.NS balance_sheet (annual, 2022-03-31) — Tangible Book Value: 168377000.00
BIOFILCHEM.NS income_statement (annual, 2022-03-31) — Tax Effect Of Unusual Items: 0.00
BIOFILCHEM.NS income_statement (annual, 2022-03-31) — Tax Provision: 3165000.00
BIOFILCHEM.NS income_statement (annual, 2022-03-31) — Tax Rate For Calcs: 0.34
BIOFILCHEM.NS balance_sheet (annual, 2022-03-31) — Taxes Receivable: 2053000.00
BIOFILCHEM.NS cash_flow (annual, 2022-03-31) — Taxes Refund Paid: -3165000.00
BIOFILCHEM.NS balance_sheet (annual, 2022-03-31) — Total Assets: 187322000.00
BIOFILCHEM.NS balance_sheet (annual, 2022-03-31) — Total Capitalization: 168377000.00
BIOFILCHEM.NS balance_sheet (annual, 2022-03-31) — Total Debt: 4647000.00
BIOFILCHEM.NS balance_sheet (annual, 2022-03-31) — Total Equity Gross Minority Interest: 168377000.00
BIOFILCHEM.NS income_statement (annual, 2022-03-31) — Total Expenses: 214773000.00
BIOFILCHEM.NS balance_sheet (annual, 2022-03-31) — Total Liabilities Net Minority Interest: 18945000.00
BIOFILCHEM.NS balance_sheet (annual, 2022-03-31) — Total Non Current Assets: 94193000.00
BIOFILCHEM.NS balance_sheet (annual, 2022-03-31) — Total Non Current Liabilities Net Minority Interest: 3997000.00
BIOFILCHEM.NS income_statement (annual, 2022-03-31) — Total Other Finance Cost: 16000.00
BIOFILCHEM.NS income_statement (annual, 2022-03-31) — Total Unusual Items: 0.00
BIOFILCHEM.NS income_statement (annual, 2022-03-31) — Total Unusual Items Excluding Goodwill: 0.00
BIOFILCHEM.NS balance_sheet (annual, 2022-03-31) — Work In Process: 1035000.00
BIOFILCHEM.NS balance_sheet (annual, 2022-03-31) — Working Capital: 78182000.00
BIOFILCHEM.NS income_statement (annual, 2023-03-31) — +Operating Expense: 18733000.00
BIOFILCHEM.NS income_statement (annual, 2023-03-31) — +Total Revenue: 300352000.00
BIOFILCHEM.NS balance_sheet (annual, 2023-03-31) — Accounts Payable: 126499000.00
BIOFILCHEM.NS balance_sheet (annual, 2023-03-31) — Accounts Receivable: 205027000.00
BIOFILCHEM.NS balance_sheet (annual, 2023-03-31) — Accumulated Depreciation: -26268000.00
BIOFILCHEM.NS balance_sheet (annual, 2023-03-31) — Additional Paid In Capital: 83331000.00
BIOFILCHEM.NS balance_sheet (annual, 2023-03-31) — Allowance For Doubtful Accounts Receivable: -848000.00
BIOFILCHEM.NS income_statement (annual, 2023-03-31) — Basic Average Shares: 16273800.00
BIOFILCHEM.NS income_statement (annual, 2023-03-31) — Basic EPS: 0.34
BIOFILCHEM.NS cash_flow (annual, 2023-03-31) — Beginning Cash Position: 1449000.00
BIOFILCHEM.NS balance_sheet (annual, 2023-03-31) — Buildings And Improvements: 29895000.00
BIOFILCHEM.NS cash_flow (annual, 2023-03-31) — Capital Expenditure: -106000.00
BIOFILCHEM.NS balance_sheet (annual, 2023-03-31) — Capital Stock: 162738000.00
BIOFILCHEM.NS balance_sheet (annual, 2023-03-31) — Cash And Cash Equivalents: 377000.00
BIOFILCHEM.NS balance_sheet (annual, 2023-03-31) — Cash Cash Equivalents And Short Term Investments: 377000.00
BIOFILCHEM.NS balance_sheet (annual, 2023-03-31) — Cash Equivalents: 0.00
BIOFILCHEM.NS balance_sheet (annual, 2023-03-31) — Cash Financial: 377000.00
BIOFILCHEM.NS cash_flow (annual, 2023-03-31) — Change In Inventory: 797000.00
BIOFILCHEM.NS cash_flow (annual, 2023-03-31) — Change In Other Current Assets: 500000.00
BIOFILCHEM.NS cash_flow (annual, 2023-03-31) — Change In Other Current Liabilities: 984000.00
BIOFILCHEM.NS cash_flow (annual, 2023-03-31) — Change In Payable: 120536000.00
BIOFILCHEM.NS cash_flow (annual, 2023-03-31) — Change In Receivables: -133290000.00
BIOFILCHEM.NS cash_flow (annual, 2023-03-31) — Change In Working Capital: -10473000.00
BIOFILCHEM.NS cash_flow (annual, 2023-03-31) — Changes In Cash: -1073000.00
BIOFILCHEM.NS balance_sheet (annual, 2023-03-31) — Common Stock: 162738000.00
BIOFILCHEM.NS balance_sheet (annual, 2023-03-31) — Common Stock Equity: 173015000.00
BIOFILCHEM.NS balance_sheet (annual, 2023-03-31) — Construction In Progress: 0.00
BIOFILCHEM.NS income_statement (annual, 2023-03-31) — Cost Of Revenue: 274233000.00
BIOFILCHEM.NS balance_sheet (annual, 2023-03-31) — Current Assets: 223541000.00
BIOFILCHEM.NS balance_sheet (annual, 2023-03-31) — Current Debt: 5223000.00
BIOFILCHEM.NS balance_sheet (annual, 2023-03-31) — Current Debt And Capital Lease Obligation: 5223000.00
BIOFILCHEM.NS balance_sheet (annual, 2023-03-31) — Current Deferred Taxes Liabilities: 2300000.00
BIOFILCHEM.NS balance_sheet (annual, 2023-03-31) — Current Liabilities: 137255000.00
BIOFILCHEM.NS balance_sheet (annual, 2023-03-31) — Current Provisions: 2300000.00
BIOFILCHEM.NS cash_flow (annual, 2023-03-31) — Depreciation: 4291000.00
BIOFILCHEM.NS cash_flow (annual, 2023-03-31) — Depreciation And Amortization: 4291000.00
BIOFILCHEM.NS income_statement (annual, 2023-03-31) — Depreciation And Amortization In Income Statement: 4291000.00
BIOFILCHEM.NS income_statement (annual, 2023-03-31) — Depreciation Income Statement: 4291000.00
BIOFILCHEM.NS income_statement (annual, 2023-03-31) — Diluted Average Shares: 16273800.00
BIOFILCHEM.NS income_statement (annual, 2023-03-31) — Diluted EPS: 0.34
BIOFILCHEM.NS income_statement (annual, 2023-03-31) — Diluted NI Availto Com Stockholders: 5604000.00
BIOFILCHEM.NS income_statement (annual, 2023-03-31) — EBIT: 8349000.00
BIOFILCHEM.NS income_statement (annual, 2023-03-31) — EBITDA: 12640000.00
BIOFILCHEM.NS cash_flow (annual, 2023-03-31) — End Cash Position: 376000.00
BIOFILCHEM.NS cash_flow (annual, 2023-03-31) — Financing Cash Flow: 151000.00
BIOFILCHEM.NS balance_sheet (annual, 2023-03-31) — Finished Goods: 5306000.00
BIOFILCHEM.NS balance_sheet (annual, 2023-03-31) — Fixed Assets Revaluation Reserve: 37621000.00
BIOFILCHEM.NS cash_flow (annual, 2023-03-31) — Free Cash Flow: -1224000.00
BIOFILCHEM.NS income_statement (annual, 2023-03-31) — General And Administrative Expense: 1363000.00
BIOFILCHEM.NS balance_sheet (annual, 2023-03-31) — Gross Accounts Receivable: 205875000.00
BIOFILCHEM.NS balance_sheet (annual, 2023-03-31) — Gross PPE: 116276000.00
BIOFILCHEM.NS income_statement (annual, 2023-03-31) — Gross Profit: 26119000.00
BIOFILCHEM.NS income_statement (annual, 2023-03-31) — Interest Expense: 419000.00
BIOFILCHEM.NS income_statement (annual, 2023-03-31) — Interest Expense Non Operating: 419000.00
BIOFILCHEM.NS income_statement (annual, 2023-03-31) — Interest Income: 16000.00
BIOFILCHEM.NS income_statement (annual, 2023-03-31) — Interest Income Non Operating: 16000.00
BIOFILCHEM.NS cash_flow (annual, 2023-03-31) — Interest Paid Cff: -425000.00
BIOFILCHEM.NS cash_flow (annual, 2023-03-31) — Interest Received Cfi: 0.00
BIOFILCHEM.NS balance_sheet (annual, 2023-03-31) — Inventory: 12134000.00
BIOFILCHEM.NS balance_sheet (annual, 2023-03-31) — Invested Capital: 178238000.00
BIOFILCHEM.NS cash_flow (annual, 2023-03-31) — Investing Cash Flow: -106000.00
BIOFILCHEM.NS balance_sheet (annual, 2023-03-31) — Land And Improvements: 44959000.00
BIOFILCHEM.NS balance_sheet (annual, 2023-03-31) — Machinery Furniture Equipment: 38989000.00
BIOFILCHEM.NS balance_sheet (annual, 2023-03-31) — Net Debt: 4846000.00
BIOFILCHEM.NS income_statement (annual, 2023-03-31) — Net Income: 5604000.00
BIOFILCHEM.NS income_statement (annual, 2023-03-31) — Net Income Common Stockholders: 5604000.00
BIOFILCHEM.NS income_statement (annual, 2023-03-31) — Net Income Continuous Operations: 5604000.00
BIOFILCHEM.NS income_statement (annual, 2023-03-31) — Net Income Discontinuous Operations: 0.00
BIOFILCHEM.NS income_statement (annual, 2023-03-31) — Net Income Extraordinary: 0.00
BIOFILCHEM.NS income_statement (annual, 2023-03-31) — Net Income From Continuing And Discontinued Operation: 5604000.00
BIOFILCHEM.NS income_statement (annual, 2023-03-31) — Net Income From Continuing Operation Net Minority Interest: 5604000.00
BIOFILCHEM.NS cash_flow (annual, 2023-03-31) — Net Income From Continuing Operations: 7930000.00
BIOFILCHEM.NS income_statement (annual, 2023-03-31) — Net Income Including Noncontrolling Interests: 5604000.00
BIOFILCHEM.NS income_statement (annual, 2023-03-31) — Net Interest Income: -409000.00
BIOFILCHEM.NS cash_flow (annual, 2023-03-31) — Net Issuance Payments Of Debt: 576000.00
BIOFILCHEM.NS cash_flow (annual, 2023-03-31) — Net Long Term Debt Issuance: 576000.00
BIOFILCHEM.NS income_statement (annual, 2023-03-31) — Net Non Operating Interest Income Expense: -409000.00
BIOFILCHEM.NS balance_sheet (annual, 2023-03-31) — Net PPE: 90008000.00
BIOFILCHEM.NS cash_flow (annual, 2023-03-31) — Net PPE Purchase And Sale: -106000.00
BIOFILCHEM.NS cash_flow (annual, 2023-03-31) — Net Short Term Debt Issuance: 576000.00
BIOFILCHEM.NS balance_sheet (annual, 2023-03-31) — Net Tangible Assets: 173015000.00
BIOFILCHEM.NS balance_sheet (annual, 2023-03-31) — Non Current Deferred Taxes Liabilities: 3787000.00
BIOFILCHEM.NS balance_sheet (annual, 2023-03-31) — Non Current Prepaid Assets: 509000.00
BIOFILCHEM.NS income_statement (annual, 2023-03-31) — Normalized EBITDA: 12640000.00
BIOFILCHEM.NS income_statement (annual, 2023-03-31) — Normalized Income: 5604000.00
BIOFILCHEM.NS cash_flow (annual, 2023-03-31) — Operating Cash Flow: -1118000.00
BIOFILCHEM.NS income_statement (annual, 2023-03-31) — Operating Income: 7386000.00
BIOFILCHEM.NS income_statement (annual, 2023-03-31) — Operating Revenue: 300352000.00
BIOFILCHEM.NS balance_sheet (annual, 2023-03-31) — Ordinary Shares Number: 16273800.00
BIOFILCHEM.NS balance_sheet (annual, 2023-03-31) — Other Current Assets: 2369000.00
BIOFILCHEM.NS balance_sheet (annual, 2023-03-31) — Other Current Liabilities: -30000.00
BIOFILCHEM.NS balance_sheet (annual, 2023-03-31) — Other Equity Interest: 10277000.00
BIOFILCHEM.NS balance_sheet (annual, 2023-03-31) — Other Inventories: -1000.00
BIOFILCHEM.NS cash_flow (annual, 2023-03-31) — Other Non Cash Items: 425000.00
BIOFILCHEM.NS balance_sheet (annual, 2023-03-31) — Other Non Current Assets: -1000.00
BIOFILCHEM.NS income_statement (annual, 2023-03-31) — Other Non Operating Income Expenses: 954000.00
BIOFILCHEM.NS income_statement (annual, 2023-03-31) — Other Operating Expenses: 6663000.00
BIOFILCHEM.NS balance_sheet (annual, 2023-03-31) — Other Payable: 3233000.00
BIOFILCHEM.NS balance_sheet (annual, 2023-03-31) — Other Properties: 2433000.00
BIOFILCHEM.NS balance_sheet (annual, 2023-03-31) — Other Short Term Investments: 117000.00
BIOFILCHEM.NS income_statement (annual, 2023-03-31) — Otherunder Preferred Stock Dividend: 0.00
BIOFILCHEM.NS balance_sheet (annual, 2023-03-31) — Payables: 129732000.00
BIOFILCHEM.NS cash_flow (annual, 2023-03-31) — Pension And Employee Benefit Expense: -966000.00
BIOFILCHEM.NS balance_sheet (annual, 2023-03-31) — Prepaid Assets: 6003000.00
BIOFILCHEM.NS income_statement (annual, 2023-03-31) — Pretax Income: 7930000.00
BIOFILCHEM.NS balance_sheet (annual, 2023-03-31) — Properties: 0.00
BIOFILCHEM.NS cash_flow (annual, 2023-03-31) — Provisionand Write Offof Assets: 0.00
BIOFILCHEM.NS cash_flow (annual, 2023-03-31) — Purchase Of PPE: -106000.00
BIOFILCHEM.NS balance_sheet (annual, 2023-03-31) — Raw Materials: 6829000.00
BIOFILCHEM.NS income_statement (annual, 2023-03-31) — Reconciled Cost Of Revenue: 274233000.00
BIOFILCHEM.NS income_statement (annual, 2023-03-31) — Reconciled Depreciation: 4291000.00
BIOFILCHEM.NS balance_sheet (annual, 2023-03-31) — Restricted Cash: 0.00
BIOFILCHEM.NS balance_sheet (annual, 2023-03-31) — Retained Earnings: -325957000.00
BIOFILCHEM.NS cash_flow (annual, 2023-03-31) — Sale Of PPE: 0.00
BIOFILCHEM.NS income_statement (annual, 2023-03-31) — Selling And Marketing Expense: 162000.00
BIOFILCHEM.NS income_statement (annual, 2023-03-31) — Selling General And Administration: 1525000.00
BIOFILCHEM.NS balance_sheet (annual, 2023-03-31) — Share Issued: 16273800.00
BIOFILCHEM.NS income_statement (annual, 2023-03-31) — Special Income Charges: 0.00
BIOFILCHEM.NS balance_sheet (annual, 2023-03-31) — Stockholders Equity: 173015000.00
BIOFILCHEM.NS balance_sheet (annual, 2023-03-31) — Tangible Book Value: 173015000.00
BIOFILCHEM.NS income_statement (annual, 2023-03-31) — Tax Effect Of Unusual Items: 0.00
BIOFILCHEM.NS income_statement (annual, 2023-03-31) — Tax Provision: 2326000.00
BIOFILCHEM.NS income_statement (annual, 2023-03-31) — Tax Rate For Calcs: 0.23
BIOFILCHEM.NS balance_sheet (annual, 2023-03-31) — Taxes Receivable: 2674000.00
BIOFILCHEM.NS cash_flow (annual, 2023-03-31) — Taxes Refund Paid: -2326000.00
BIOFILCHEM.NS balance_sheet (annual, 2023-03-31) — Total Assets: 314057000.00
BIOFILCHEM.NS balance_sheet (annual, 2023-03-31) — Total Capitalization: 173015000.00
BIOFILCHEM.NS balance_sheet (annual, 2023-03-31) — Total Debt: 5223000.00
BIOFILCHEM.NS balance_sheet (annual, 2023-03-31) — Total Equity Gross Minority Interest: 173015000.00
BIOFILCHEM.NS income_statement (annual, 2023-03-31) — Total Expenses: 292966000.00
BIOFILCHEM.NS balance_sheet (annual, 2023-03-31) — Total Liabilities Net Minority Interest: 141042000.00
BIOFILCHEM.NS balance_sheet (annual, 2023-03-31) — Total Non Current Assets: 90516000.00
BIOFILCHEM.NS balance_sheet (annual, 2023-03-31) — Total Non Current Liabilities Net Minority Interest: 3787000.00
BIOFILCHEM.NS income_statement (annual, 2023-03-31) — Total Other Finance Cost: 6000.00
BIOFILCHEM.NS income_statement (annual, 2023-03-31) — Total Unusual Items: 0.00
BIOFILCHEM.NS income_statement (annual, 2023-03-31) — Total Unusual Items Excluding Goodwill: 0.00
BIOFILCHEM.NS balance_sheet (annual, 2023-03-31) — Work In Process: 0.00
BIOFILCHEM.NS balance_sheet (annual, 2023-03-31) — Working Capital: 86286000.00
BIOFILCHEM.NS income_statement (annual, 2024-03-31) — +Operating Expense: 21106000.00
BIOFILCHEM.NS income_statement (annual, 2024-03-31) — +Total Revenue: 400353000.00
BIOFILCHEM.NS balance_sheet (annual, 2024-03-31) — Accounts Payable: 275549000.00
BIOFILCHEM.NS balance_sheet (annual, 2024-03-31) — Accounts Receivable: 330291000.00
BIOFILCHEM.NS balance_sheet (annual, 2024-03-31) — Accumulated Depreciation: -30262000.00
BIOFILCHEM.NS balance_sheet (annual, 2024-03-31) — Additional Paid In Capital: 83331000.00
BIOFILCHEM.NS balance_sheet (annual, 2024-03-31) — Allowance For Doubtful Accounts Receivable: -1276000.00
BIOFILCHEM.NS income_statement (annual, 2024-03-31) — Basic Average Shares: 16118182.00
BIOFILCHEM.NS income_statement (annual, 2024-03-31) — Basic EPS: 0.44
BIOFILCHEM.NS cash_flow (annual, 2024-03-31) — Beginning Cash Position: 376000.00
BIOFILCHEM.NS balance_sheet (annual, 2024-03-31) — Buildings And Improvements: 30116000.00
BIOFILCHEM.NS cash_flow (annual, 2024-03-31) — Capital Expenditure: -229000.00
BIOFILCHEM.NS balance_sheet (annual, 2024-03-31) — Capital Stock: 162738000.00
BIOFILCHEM.NS balance_sheet (annual, 2024-03-31) — Cash And Cash Equivalents: 22835000.00
BIOFILCHEM.NS balance_sheet (annual, 2024-03-31) — Cash Cash Equivalents And Short Term Investments: 22835000.00
BIOFILCHEM.NS balance_sheet (annual, 2024-03-31) — Cash Equivalents: 0.00
BIOFILCHEM.NS balance_sheet (annual, 2024-03-31) — Cash Financial: 22835000.00
BIOFILCHEM.NS cash_flow (annual, 2024-03-31) — Change In Inventory: -13363000.00
BIOFILCHEM.NS cash_flow (annual, 2024-03-31) — Change In Other Current Assets: 551000.00
BIOFILCHEM.NS cash_flow (annual, 2024-03-31) — Change In Other Current Liabilities: -459000.00
BIOFILCHEM.NS cash_flow (annual, 2024-03-31) — Change In Payable: 149050000.00
BIOFILCHEM.NS cash_flow (annual, 2024-03-31) — Change In Receivables: -125264000.00
BIOFILCHEM.NS cash_flow (annual, 2024-03-31) — Change In Working Capital: 10515000.00
BIOFILCHEM.NS cash_flow (annual, 2024-03-31) — Changes In Cash: 22459000.00
BIOFILCHEM.NS balance_sheet (annual, 2024-03-31) — Common Stock: 162738000.00
BIOFILCHEM.NS balance_sheet (annual, 2024-03-31) — Common Stock Equity: 182028000.00
BIOFILCHEM.NS balance_sheet (annual, 2024-03-31) — Construction In Progress: 0.00
BIOFILCHEM.NS income_statement (annual, 2024-03-31) — Cost Of Revenue: 381209000.00
BIOFILCHEM.NS balance_sheet (annual, 2024-03-31) — Current Assets: 384076000.00
BIOFILCHEM.NS balance_sheet (annual, 2024-03-31) — Current Debt: 4389000.00
BIOFILCHEM.NS balance_sheet (annual, 2024-03-31) — Current Debt And Capital Lease Obligation: 4389000.00
BIOFILCHEM.NS balance_sheet (annual, 2024-03-31) — Current Deferred Taxes Liabilities: 2400000.00
BIOFILCHEM.NS balance_sheet (annual, 2024-03-31) — Current Liabilities: 285245000.00
BIOFILCHEM.NS balance_sheet (annual, 2024-03-31) — Current Provisions: 2400000.00
BIOFILCHEM.NS cash_flow (annual, 2024-03-31) — Depreciation: 3994000.00
BIOFILCHEM.NS cash_flow (annual, 2024-03-31) — Depreciation And Amortization: 3994000.00
BIOFILCHEM.NS income_statement (annual, 2024-03-31) — Depreciation And Amortization In Income Statement: 3994000.00
BIOFILCHEM.NS income_statement (annual, 2024-03-31) — Depreciation Income Statement: 3994000.00
BIOFILCHEM.NS income_statement (annual, 2024-03-31) — Diluted Average Shares: 16273800.00
BIOFILCHEM.NS income_statement (annual, 2024-03-31) — Diluted EPS: 0.44
BIOFILCHEM.NS income_statement (annual, 2024-03-31) — Diluted NI Availto Com Stockholders: 7092000.00
BIOFILCHEM.NS income_statement (annual, 2024-03-31) — EBIT: 9068000.00